Franchise Facts Report

Franchise Facts Reportbrands → Galt Pharmaceuticals

Galt Pharmaceuticals franchise — is it worth it?

Other · FDD-based assessment · registered 2024

Risk level — in the report

GALT PHARMACEUTICALS offers a franchise opportunity in the 'Other' category with an initial investment ranging from $219,950 to $242,200.

Get the full report — $99what's inside ↓
Total initial investment
$219,950 – $242,200
Above the other median · median $198,600
Initial franchise fee
$100,000
FDD Item 5
Royalty
6%
FDD Item 6
Item 19 earnings
Not disclosed
no franchisor earnings
Litigation (Item 3)
Not determined
Item 3 not machine-read
Outlet network
66 units
+2 last year
The full Galt Pharmaceuticals report — $99

Unlock what the free page above only hints at:

Compare 3 brands — $249 See a sample report

Figures above are as disclosed in Galt Pharmaceuticals's most recent FDD (registered 2024). Source: California Dept. of Financial Protection and Innovation — Franchise Registration · filing app-31917. The risk level, the Item 19 figures, how it compares to peers, and the litigation & churn detail are in the full report.

Galt Pharmaceuticals franchise profit — what the FDD discloses

Plainly: Galt Pharmaceuticals does not disclose franchise profit or revenue. Its most recent FDD makes no Item 19 financial performance representation, so there is no franchisor-backed earnings figure for Galt Pharmaceuticals — any number quoted elsewhere is an estimate, not a disclosure. The absence is itself worth weighing (many other franchisors do disclose), and the full report reads the risk signals Galt Pharmaceuticals's FDD does contain — fees, litigation, and outlet churn — against peers. For brands that put earnings on paper, see Other franchises with disclosed Item 19 earnings.

Galt Pharmaceuticals lawsuits & legal history (FDD Item 3)

We do not publish a litigation answer for Galt Pharmaceuticals. Item 3 could not be read reliably from this particular filing, and a claim that a company has no legal history is not one to make on a failed parse — so we say we do not know instead. Item 3 of the FDD itself is the place to check; the methodology page explains what we do and do not machine-read.

Galt Pharmaceuticals closures & failure rate

Before you sign, Galt Pharmaceuticals will hand you a list of current owners to call as references — and they choose who's on that list. It won't include the owners who quit, got bought out, or were forced out last year. The FDD does report that number, even though the reference list leaves those people off. Below is what Galt Pharmaceuticals's most recent filing shows, and whether it's normal for a other of this kind.

The closest thing an FDD has to a failure rate is Item 20 — outlet openings, closures, terminations and non-renewals, reported by the franchisor. Galt Pharmaceuticals's latest tables show a growing franchised network. The actual closure and termination counts, and how Galt Pharmaceuticals's churn ranks against other peers, are in the full report.

The full Galt Pharmaceuticals report — $99

The risk & red-flag breakdown, every figure ranked against other peers, litigation and churn detail — emailed as a PDF.

Who owns Galt Pharmaceuticals?

Galt Pharmaceuticals's franchise is offered by GALT PHRANCHISE SYSTEMS, LLC — the franchisor named on the cover of its most recently filed Franchise Disclosure Document (2024), and the entity a franchisee actually signs with. That name comes straight off the filing at CA DFPI; it identifies the franchisor, not necessarily the ultimate parent company behind it.

Franchises at a similar investment level at a similar investment level

Anyone weighing Galt Pharmaceuticals is really weighing it against the other brands their money could go into. These are the closest by total initial investment (FDD Item 7), each with its own FDD-based page.

All States M.E.D.$188,500 – $255,500 · Item 19 disclosedAerus | Aerus Electrolux | Lux$30,500 – $417,790Shrunk 3D$187,485 – $267,235 · Item 19 disclosedCraters & Freighters$173,350 – $287,500CORE Group Restoration - Member$92,400 – $378,750AcuSpray$148,045 – $326,125Extreme Art Studio$119,030 – $355,455Game Truck$164,450 – $312,199Coopers Scoopers, LLC - AR$159,650 – $320,400Garage Kings®$311,544 – $388,794 · Item 19 disclosedFully Promotedinvestment not disclosed · Item 19 disclosedFunboxinvestment not disclosed

Galt Pharmaceuticals franchise — frequently asked

Who owns Galt Pharmaceuticals — who is the franchisor?

Galt Pharmaceuticals's most recently filed FDD (2024) names GALT PHRANCHISE SYSTEMS, LLC as the franchisor — the entity you would actually sign the franchise agreement with, as stated on the disclosure document itself. A registry filing names the franchisor, not necessarily its ultimate parent company.

How much does a Galt Pharmaceuticals franchise cost?

Galt Pharmaceuticals's most recently filed FDD (Item 7) puts the total estimated initial investment at $219,950 – $242,200, with an initial franchise fee of $100,000 and a 6% royalty. That price is the franchisor's own estimate of what it takes to open, not a quote. The full report breaks down every fee line and benchmarks it against other peers.

How much profit does a Galt Pharmaceuticals franchise make?

Galt Pharmaceuticals makes no Item 19 financial performance representation, so there is no franchisor-disclosed revenue or profit figure for Galt Pharmaceuticals at all — and profit would never be disclosed even where earnings are, because it depends on your rent, labour and how you operate. Any profit figure quoted elsewhere is an estimate, not a disclosure.

Does Galt Pharmaceuticals disclose financial performance (Item 19)?

No — Galt Pharmaceuticals's most recent FDD makes no Item 19 financial performance representation. Its absence is worth weighing; the report focuses on the verifiable risk signals instead.

Are there lawsuits against Galt Pharmaceuticals?

We do not publish a litigation answer for Galt Pharmaceuticals: Item 3 could not be read reliably from this filing, and we would rather say so than assert a clean record we have not verified. Item 3 of the FDD itself is the place to check.

Is Galt Pharmaceuticals a good franchise to buy?

That comes down to how Galt Pharmaceuticals's investment, earnings, litigation and franchisee churn stack up against other peers — which is exactly what the full report answers. For $99 you get the risk level and what's driving it, the actual Item 19 earnings (absent from this FDD), where every figure ranks against peers, and the specific questions to ask the franchisor before you sign.

Decide with the numbers — $99

Everything the sections above point to, in one place: Galt Pharmaceuticals's risk level and what's driving it, what the missing Item 19 earnings imply, every figure ranked against other peers, and the litigation & churn detail — with the questions to put to the franchisor before you sign.

Compare 3 brands — $249
Not ready to spend $99 yet?

Get a free email when something changes on Galt Pharmaceuticals or other: a new FDD registration, a new lawsuit, an outlet count that shifts, or Item 19 earnings going from undisclosed to disclosed. Pulled straight from the same registries every report is built on.

This report compiles and structures publicly filed Franchise Disclosure Document (FDD) data from state franchise registrations. It is not legal, financial, or investment advice, is not affiliated with or endorsed by any franchisor, and does not replace reading the full FDD or consulting a franchise attorney or accountant. All figures are as disclosed by the franchisor in its most recent registered FDD. Item 19 financial performance representations are made at the franchisor’s option and may be absent or limited.